.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Fuji
US Army
Medtronic
McKesson
Julphar
Harvard Business School
Argus Health
UBS
Merck

Generated: July 27, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Continuous intravenous infusion of adenosine to human patients undergoing percutaneous transluminal angioplasty
Abstract:This invention is concerned with the use of adenosine as an agent for the treatment of human beings. More particularly, this invention is concerned with the administration of adenosine to human patients by continuous intravenous infusion for, inter alia, control of blood pressure, use as a selective vasodilator, decreasing pulmonary vascular resistance, treating acute pulmonary hypertension in conjunction with idiopathic respiratory distress syndrome, in diagnosing pulmonary hypertension in conjunction with cardiac septum defects, in percutaneous transluminal angioplasty (PTCA), in coronary thrombolysis (CTL) and in radionucleide scintography.
Inventor(s): Sollevi; Alf (Bromma, SE)
Assignee: Item Development Aktiebolag (Stocksund, SE)
Filing Date:Dec 15, 1993
Application Number:08/167,745
Claims:1. In a method for percutaneous transluminal angioplasty (PTCA), for treating coronary artery disease in a human patient comprising inserting a catheter having an inflatable balloon into a coronary artery which has an angiographically demonstrable stenosis, and inflating the balloon, the improvement of administering adenosine to said patient by continuous intravenous infusion to lessen negative effects of said PTCA.

2. A method as claimed in claim 1 wherein adenosine is infused into a peripheral vein.

3. A method as claimed in claim 1 wherein administration of adenosine is begun shortly before the PTCA procedure and continued during and several hours after said procedure.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
UBS
Cerilliant
McKinsey
AstraZeneca
Argus Health
Citi
Baxter
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot